Please assess the completion status of the following clinical trial:

Trial Title: PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation (cAVM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All patients with a ruptured or unruptured and previously endovascularly untreated cAVM that are eligible for endovascular treatment with PHIL® alone or in conjunction with N-Butyl cyanoacrylate glue (NBCA) and/or coils (e.g. if pressure cooking technique is needed or used).~2. All patients with a previously endovascularly treated cAVM in which NBCA and/or coils (but not another non-adhesive liquid embolic agent) have been used may be included.\*\*~3. All patients with a remaining cAVM, ruptured or unruptured, that has previously been treated with NS and/or RT may be included.~4. Patient or patient's legally authorized representative has received information about data collection and has signed and dated an Informed Consent Form. (Based on the country's regulation).~Exclusion Criteria:~1. cAVM not eligible for endovascular treatment~2. cAVM previously treated with a non-adhesive liquid embolic agent other than PHIL®~3. Treatment requiring the use of any other non-adhesive embolic liquid~4. Patient is allergic to iodine~5. Premature and newborn infant~6. Patient with renal failure or significant liver impairment~7. Patient is participating in another study evaluating other medical devices, other procedures or medications.~8. Any other condition that might prevent patient participation in the study or follow up~9. Patient does not want to and/or refuses to give consent to the collection and processing of data required for centralized monitoring

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).